Published in J Infect Dis on May 15, 2011
Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men | NCT00696618
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog (2016) 1.40
Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther (2015) 1.29
Does ART prevent HIV transmission among MSM? AIDS (2012) 1.20
CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu Rev Med (2011) 1.13
Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS (2013) 1.08
Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr (2013) 1.07
HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med (2012) 1.03
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med (2015) 0.99
Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol (2013) 0.99
CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers. Drug Metab Dispos (2014) 0.98
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol (2014) 0.95
Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol (2015) 0.95
Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis (2013) 0.94
Next-generation oral preexposure prophylaxis: beyond tenofovir. Curr Opin HIV AIDS (2012) 0.92
Current perspectives in HIV post-exposure prophylaxis. HIV AIDS (Auckl) (2014) 0.89
Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens. J Int AIDS Soc (2015) 0.87
Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr (2012) 0.87
Models for predicting effective HIV chemoprevention in women. J Acquir Immune Defic Syndr (2015) 0.87
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology (2014) 0.87
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta (2014) 0.86
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet (2014) 0.86
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. Antimicrob Agents Chemother (2011) 0.84
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr (2013) 0.84
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. J Int AIDS Soc (2016) 0.83
Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques. J Antimicrob Chemother (2015) 0.82
Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. Expert Opin Pharmacother (2013) 0.81
Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? Philos Trans R Soc Lond B Biol Sci (2014) 0.81
Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention. Pharm Res (2015) 0.78
The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) (2012) 0.78
HIV PrEP Trials: The Road to Success. Clin Investig (Lond) (2013) 0.77
Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing. Biochem Pharmacol (2016) 0.76
A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. Malar J (2012) 0.75
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol (2008) 1.85
HIV-1 vaccine development after STEP. Annu Rev Med (2010) 1.64
The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides. AIDS Behav (2007) 1.61
Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis (2010) 1.55
Drug transfer through mucus. Adv Drug Deliv Rev (2001) 1.32
A new rectal model for dosimetry applications. J Nucl Med (1999) 1.23
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS (2004) 1.22
Safety and effectiveness of large-volume enema solutions. Appl Nurs Res (2004) 1.17
Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin Pharmacol Ther (2007) 1.05
Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica (2008) 1.03
Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect (2008) 1.01
Effect of semen sampling frequency on seminal antiretroviral drug concentration. Clin Pharmacol Ther (2007) 1.01
Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit (2007) 0.90
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76
Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66
Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Quality indicators for colonoscopy. Gastrointest Endosc (2014) 4.17
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointest Endosc (2010) 3.74
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Surplus men, sex work, and the spread of HIV in China. AIDS (2005) 3.64
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis (2006) 3.17
Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol (2007) 2.94
American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.79
Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol (2012) 2.70
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol (2009) 2.53
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. J Acquir Immune Defic Syndr (2011) 2.49
Influence of race and gender on the presentation of eosinophilic esophagitis. Am J Gastroenterol (2011) 2.47
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis (2006) 2.44
Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43
Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 2.38
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis (2005) 2.31
Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen. Sex Transm Dis (2006) 2.31
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 2.28
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
China's syphilis epidemic: a systematic review of seroprevalence studies. Sex Transm Dis (2006) 2.23
American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.23
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr (2007) 2.17
Prevalence of HIV infection among young adults in the United States: results from the Add Health study. Am J Public Health (2006) 2.17
Digestive and liver diseases statistics, 2004. Gastroenterology (2004) 2.14
Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect Dis (2010) 2.13
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One (2011) 2.06
Quality indicators for colonoscopy. Am J Gastroenterol (2014) 2.06
Keep them in school: the importance of education as a protective factor against HIV infection among young South African women. Int J Epidemiol (2008) 2.00
Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis (2005) 1.95
A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology (2009) 1.95
Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS (2007) 1.89
Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82
Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc (2010) 1.79
HIV incidence among men who have sex with men in China: a meta-analysis of published studies. PLoS One (2011) 1.79
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet (2009) 1.77
Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol (2013) 1.75
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol (2003) 1.73
Inter- and intraobserver reliability and validation of a new method for determination of eosinophil counts in patients with esophageal eosinophilia. Dig Dis Sci (2009) 1.70
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia. Gastrointest Endosc (2012) 1.67
Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.67
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Reduced polyp detection as endoscopy shift progresses: experience with screening colonoscopy at a tertiary-care hospital. J Clin Gastroenterol (2011) 1.66
Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology (2012) 1.65
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65
The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin Gastroenterol Hepatol (2012) 1.64
HIV treatment as prevention: to be or not to be? J Acquir Immune Defic Syndr (2010) 1.59
Development and validation of a PCR-based enzyme-linked immunosorbent assay with urine for use in clinical research settings to detect Trichomonas vaginalis in women. J Clin Microbiol (2002) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr (2013) 1.56
Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55